Based in the UK, Theraimmune is using AI to identify genetic features that enable ‘healthier ageing’ in menopausal women, aiming to develop new therapies and repurposing drugs for age-related conditions.
They want to revolutionize clinical practice and fill critical gaps in women’s health research. They offer personalized treatments and enhance the quality of life for millions of women globally by helping develop therapies and drugs that target high-risk features.
Theraimmune uses AI-assisted hypergraph analysis, deep learning, perturbation analysis and more to understand complex biological and genetic features among women. By identifying high-risk individuals through family history, biomarkers, and clinical tests, Theraimmune can tailor preventive strategies and interventions, improving health outcomes for menopausal women.
Theraimmune will use Northern Data Group’s AI Accelerator to build and scale its pipeline.